Current address: Shinji Tomita, MD, Cardiothoracic Surgical Unit, Level 4, Auckland City Hospital, Auckland, New Zealand

Fukuhara, Shinya; Tomita, Shinji; Nakatani, Takeshi; Fujisato, Toshiya; Ohtsu, Yoshinori; Ishida, Michiko; Yutani, Chikao; Kitamura, Soichiro

doi:10.1253/circj.69.850

Cited by 36 publications

(8 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The matrix of the scaffold is usually composed of naturally occurring biomaterials such as collagen and fibrin [45], but can also be created from synthetic polymers [46–49], and the scaffold can be modified for delivery of growth factors and other cytokines that may further improve angiogenesis, impede apoptosis, and activate endogenous repair mechanisms. However, scaffolds do not produce patches with well-aligned CMs, and the scaffold material may interfere with electronic signal transduction.…”

Section: Methods Of Patch Creationmentioning

confidence: 99%

Engineered Tissue Patch for Cardiac Cell Therapy

Zhang

2015

Curr Treat Options Cardio Med

View full text Add to dashboard Cite

Opinion statement Cell therapy can be administered via injections delivered directly into the myocardium or as engineered cardiac tissue patches, which are the subject of this review. Engineered cardiac patches can be created from sheets of interconnected cells or by suspending the cells in a scaffold of material that is designed to mimic the native extracellular matrix. The sheet-based approach produces patches with well-aligned and electronically coupled cardiomyocytes, but cell-containing scaffolds are more readily vascularized by the host's circulatory system and, consequently, are currently more suitable for applications that require a thicker patch. Cell patches can also be modified for the co-delivery of peptides that may promote cell survival and activate endogenous repair mechanisms; nevertheless, techniques for controlling inflammation, limiting apoptosis, and improving vascular growth need continue to be developed to make it a therapeutic modality for patients with myocardial infarction.

show abstract

Section: Methods Of Patch Creationmentioning

confidence: 99%

Engineered Tissue Patch for Cardiac Cell Therapy

Zhang

2015

Curr Treat Options Cardio Med

View full text Add to dashboard Cite

show abstract

“…Polygycolic acid (PGA) 68 , poly ε-caprolactone-co-l-lactide (PCLA) 69 , poly-glycerolsebacate (PGS) 66 , and polydimethylsiloxane (PDMS) 94 have been extensively used as tissue engineering substrates. These materials typically must be coated with extracellular matrix proteins to enable cardiomyocyte attachment and have many of the same limitations associated with biological matrices (as described above) for heart-muscle engineering on a macroscopic scale.…”

Section: Scaffold-based Approachesmentioning

confidence: 99%

Patching the Heart

Zimmermann

Garry

et al. 2013

Circulation Research

129

View full text Add to dashboard Cite

Transplantation of engineered tissue patches containing either progenitor cells or cardiomyocytes for cardiac repair is emerging as an exciting treatment option for patients with postinfarction left ventricular (LV) remodeling. The beneficial effects may evolve directly from remuscularization or indirectly through paracrine mechanisms that mobilize and/or activate endogenous progenitor cells to promote neovascularization and remuscularization, inhibit apoptosis, and attenuate LV dilatation and disease progression. Despite encouraging results, further improvements are necessary to enhance current tissue-engineering concepts and techniques and to achieve clinical impact. Herein, we review several strategies for cardiac remuscularization and paracrine support that can induce cardiac repair and attenuate LV dysfunction from both within and outside the myocardium.

show abstract

“…The bFGF-BMSC-scaffold group obtained the highest density vessel formation and the best cardiac function, leading to a better improvement with respect to the BMSC-scaffold group 1 month after treatment. 131 A porous collagen scaffold incorporate VEGF and FGF in combination with MSC. The system was tested in a rat model of MI.…”

Section: Growth Factor Delivery Systems and Cell Therapymentioning

confidence: 99%